32 Bio Sciences offers a quantitative diagnostic platform that uses mass spectrometry and machine learning to analyze functional metabolites in stool samples, providing actionable health scores and personalized intervention guidance for gut microbiome health. The company also develops microbiome-based interventions, including novel non-antibiotic antimicrobials, to restore microbiome balance and treat diseases.
Funding
$6M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Current methods for assessing gut microbiome health lack clinical utility and quantitative precision, preventing clinicians from identifying the root causes of dysbiosis. This diagnostic gap hinders the development of targeted interventions and the effective management of diseases linked to an imbalanced gut microbiome.
Solution
32 Bio Sciences provides a comprehensive platform for microbiome-based diagnostics and therapeutics, aiming to establish the gut microbiome as a recognized vital organ. The company's GB diagnostic platform utilizes mass spectrometry and machine learning to quantify functional metabolites in stool samples, offering actionable health scores and personalized guidance for interventions. Complementing this, their therapeutic platform focuses on developing microbiome-based interventions (MBIs), including novel non-antibiotic antimicrobials, to restore microbiome balance and treat a range of diseases. By translating advanced microbiome science into clinically applicable solutions, 32 Bio Sciences seeks to improve health span and longevity.
Target Audience
The primary target audience includes healthcare providers seeking precise diagnostic tools for microbiome-related conditions and patients looking for personalized approaches to manage and improve their gut health.
Features
- **GB Diagnostic Platform:** A quantitative, mass spectrometry-based stool test that measures functional metabolites to assess gut microbiome health.
- **Functional Metabolite Analysis:** Identifies key metabolites produced by the gut microbiome that regulate critical cellular functions, providing a measure of the microbiome's activity.
- **Actionable Health Scores:** Generates composite scores based on functional metabolite profiles, offering a quantitative assessment of gut microbiome health with established reference ranges.
- **Personalized Intervention Guidance:** Provides data-driven insights to tailor dietary changes, therapeutic strategies, and nutritional product recommendations.
- **Microbiome-Based Interventions (MBIs):** Development of novel therapeutics, including a non-antibiotic antimicrobial (CS-0003), designed to suppress bacterial virulence and restore microbiome balance.
- **CS-0003 Mechanism:** A phosphorylated triblock copolymer that mimics high-phosphate environments to suppress bacterial virulence gene expression via the PstS-PhoB pathway.
- **Targeted Disease Areas:** Focus on gastrointestinal diseases, infectious diseases (e.g., surgical site infections, sepsis), and oncology, addressing unmet needs in microbiome medicine.
- **Collaborative Research:** Leverages partnerships with academic institutions for scientific validation and platform development.